Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/182)
  • Patent number: 10344049
    Abstract: A compound and pharmaceutically acceptable salts thereof for treating cancer, having a structure represented by the following formula (I) or formula (II): in which X and Y each individually represent: R1, R2, R3, R4, and R5 individually represents hydrogen atom, acyl having 20 or less carbon atoms, alkyl having 20 or less carbon atoms, alkanoyl having 20 or less carbon atoms, aroyl having 20 or less carbon atoms, aryl having 20 or less carbon atoms, aralkyl having 20 or less carbon atoms, sulfonyl having 20 or less carbon atoms, phosphonyl having 20 or less carbon atoms, or haloacyl having 20 or less carbon atoms.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: July 9, 2019
    Assignee: AQUAVAN TECHNOLOGY CO., LTD
    Inventors: Shi-Yie Cheng, Yao-Ting Wang, Kuo-Tang Tseng, Wen-Hung Chen, Hsin Ju Wang
  • Patent number: 10278977
    Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: May 7, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
  • Patent number: 10273263
    Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 30, 2019
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Patent number: 10246481
    Abstract: Provided herein, inter alia, are methods for the preparation of modulators of farnesoid X receptor (FXR), and compositions and uses of the modulators of FXR.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 2, 2019
    Assignee: CITY OF HOPE
    Inventors: Donna Yu, Barry Forman
  • Patent number: 10238664
    Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: March 26, 2019
    Assignee: Duke University
    Inventor: Eric J. Benner
  • Patent number: 10231982
    Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 19, 2019
    Assignee: Pop Test Oncology Limited Liability Company
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10201550
    Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: February 12, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
  • Patent number: 10202414
    Abstract: The present invention relates to processes for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate thereof, wherein the dashed bond (----) at position 7 indicates that the substituent is in an ? or ? stereochemistry; R is hydrogen or hydroxy; and R1 is hydrogen or C1-C6 alkyl
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: February 12, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioello
  • Patent number: 10156564
    Abstract: Among the various aspects of the present disclosure is the provision of methods of detecting biomarkers of endoplasmic reticulum (ER) stress-associated kidney diseases. Another aspect of the present disclosure provides for a method of treating an endoplasmic reticulum (ER) stress-associated kidney disease in a subject.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 18, 2018
    Assignee: Washington University
    Inventors: Ying Chen, Yeawon Kim
  • Patent number: 10143721
    Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: December 4, 2018
    Assignees: The Population Council, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Barry R. O'Keefe, Melissa Robbiani, José A. Fernández Romero
  • Patent number: 10144757
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 4, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 10144759
    Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: December 4, 2018
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Shunlin Ren, William M. Pandak
  • Patent number: 10143938
    Abstract: The present application relates to a method for obtaining a mixture of estrogens from the pregnant mare's urine.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: December 4, 2018
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Chandrashaker Akula, John Lomans, Madhukiran Tummidi, Prashant Anil Tatake
  • Patent number: 10071108
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: September 11, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • Patent number: 10064876
    Abstract: Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 4, 2018
    Assignee: Vanderbilt University
    Inventors: Aurelio Galli, Heinrich J. G. Matthies, Naji N. Abumrad, India A. Reddy, Charles Robb Flynn, Kevin Erreger
  • Patent number: 9987291
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: June 5, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9974866
    Abstract: The present invention provides polymer-polypeptide conjugates comprising a poly(2-oxazoline) amphiphilic block copolymer linked to a polypeptide and methods of use thereof.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: May 22, 2018
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Alexander V. Kabanov, Jing Tong
  • Patent number: 9949986
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: April 24, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9895380
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: February 20, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • Patent number: 9889101
    Abstract: A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: February 13, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Paul F. Lambert, SangHyuk Chung
  • Patent number: 9867836
    Abstract: Increasing fertility in a mammal utilizes cationic steroidal antimicrobial (CSA) compounds and CSA-containing compositions. Such treatment in a mammal includes administering a formulation (e.g., lavage and/or infusion) including at least one CSA compound, or pharmaceutically acceptable salt thereof, to the reproductive structure(s) of the mammal (e.g., horse, dairy cow, human, etc.). The formulation may be applied topically as lavage and/or infusion to desired reproductive structures, such as the vagina, cervix, uterus, penis, or combinations thereof. The formulation may kill both planktonic and biofilm forms of sperm killing microbes, and may at least partially break up a microbial plaque or film located within any of the reproductive structures (e.g., the uterus).
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: January 16, 2018
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Chad S. Beus, Paul B. Savage
  • Patent number: 9770404
    Abstract: The present invention relates to a cosmetic composition for skin whitening and anti-aging, which contains 2 or more of collagen peptides, snake needle grass extract, and white ginseng saccharides as effective ingredients, improves skin resilience by increasing the content of collagen in the skin and suppresses the growth of melanin cells, improves skin brightness and uniformity, and alleviates skin yellowness and redness, so as to provide the effect of making the skin appear clearer and more radiant.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: September 26, 2017
    Assignee: Amorepacific Corporation
    Inventors: Kuan Chi Hsu, Hyeon Chung Kim, Sung II Park, Youn Joon Kim, Sang Hoon Han
  • Patent number: 9763964
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: September 19, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Patent number: 9758503
    Abstract: A compound with antitumor activities is represented by formula A or formula B R1, R2, R3, and R4 are independently hydrogen, hydroxyl, alkoxy, halogen, formyl, unsubstituted or substituted alkyl, or unsubstituted or substituted cycloalkyl.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: September 12, 2017
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Chengyuan Liang, Danni Tian, Minyi Jia, Xuechuan Wang, Xiaolin Xie, Dezhu Zhang
  • Patent number: 9700051
    Abstract: The present invention relates to the use of a compound chosen from squalamine and a squalamine-analog aminosteroid compound as agent for disinfecting an inert material object, in particular for the pre-disinfection of medical, dental, diagnostic or surgical equipment. The present invention also provides an aqueous or water-soluble disinfecting composition beneficial for a use according to the invention, characterized in that as disinfecting active compound it comprises a said antibacterial and antifungal compound selected from squalamine and a said squalamine-analog aminosteroid compound and suitable excipients for a water-soluble or aqueous formulation.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: July 11, 2017
    Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE, UNIVERSITE D'AIX MARSEILLE, FONDATION MEDITERRANEE INFECTION
    Inventors: Jean-Michel Brunel, Didier Raoult, Jean-Marc Rolain
  • Patent number: 9683008
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: June 20, 2017
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9670244
    Abstract: This invention relates, for example, to synthetic oxysterols. Also described are methods for using the compounds, including treating subjects in need thereof, and pharmaceutical compositions and kits for implementing methods of the invention.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: June 6, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Farhad Parhami, Michael E. Jung, Jennifer R. Dwyer, Khanhlinh Nguyen
  • Patent number: 9650409
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 16, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Patent number: 9636349
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: May 2, 2017
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9603858
    Abstract: The present invention relates to methods of treating, preventing, or decreasing the occurrence of a condition characterized by Th2 overactivation or impaired Th1, or mitigating symptoms associated with a condition characterized by Th2 overactivation or impaired Th1, comprising orally administering to a subject in need thereof an effective amount of a composition comprising a plant stanol and/or plant stanol ester. The present invention also relates to methods of improving the health status of a subject suffering from asthma and increasing the levels of IL-10 in a subject in need thereof.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: March 28, 2017
    Assignee: RAISIO NUTRITION LTD.
    Inventors: Florence Brull, Ronald P. Mensink, Jogehum Plat
  • Patent number: 9561199
    Abstract: The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: February 7, 2017
    Inventor: Alan B Cash
  • Patent number: 9540414
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: January 10, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Patent number: 9539203
    Abstract: The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: January 10, 2017
    Assignee: UCL BUSINESS PLC
    Inventors: Francesca Cordeiro, Stephen Moss
  • Patent number: 9532994
    Abstract: The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and methods to treat patients to maintain bone mass, enhance bone formation and/or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents, such as bone morphogenic proteins, known to assist in bone formation. The invention further includes medicaments including oxysterols for the treatment of bone disorders and implants to facilitate bone repair.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: January 3, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Farhad Parhami
  • Patent number: 9522155
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 20, 2016
    Assignee: KYTHERA BIOPHARMACEUTICALS, INC.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9505798
    Abstract: Steroid compounds are disclosed that have a formula represented by the following: and wherein m, n, t, u1, u2, v1, v2, R1a, R1b, R2a, R2b, R3a, R3b, R3c, R3d, and Y are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the treatment or prevention of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: November 29, 2016
    Assignees: New York University, Memorial Sloan-Kettering Cancer Center
    Inventors: Dan R. Littman, Jun R. Huh, Nicolas Gabriel Albert Manel, Daniel A. Ryan, David Y. Gin, Mary S. Gin, Michael R. Krout
  • Patent number: 9498183
    Abstract: Methods and devices are disclosed that, in various embodiments and permutations and combinations of inventions, diagnose and treat Pulmonary Embolism or associated symptoms. In one series of embodiments, the invention consists of methods and devices for identifying patients whose Pulmonary Embolism or associated symptoms are caused or exacerbated, at least in part, by blockages of one or more of the patient's internal pulmonary veins. In some instances, stenoses or other flow limiting structures or lesions in the patient's affected veins are identified. Further, in some instances the nature of such lesions and whether there is a significant disruption of blood pressure, or both, is ascertained. In some embodiments, methods and devices for applying one or more therapies to the blockages in the patient's pulmonary veins are provided.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: November 22, 2016
    Assignee: Volcano Corporation
    Inventors: Joe E. Brown, Marja Pauliina Margolis, Mary L. Gaddis
  • Patent number: 9375437
    Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms, pharmaceutical kits, and related methods. In one embodiment, an oral dosage form formulated for on-going administration is provided. The oral dosage form includes an amount of progesterone and a pharmaceutically acceptable carrier. The oral dosage form is formulated such that upon single dose administration to a non-pregnant woman in follicular phase, the oral dosage form provides a serum progesterone C24h of at least 0.20 ng/mL.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: June 28, 2016
    Assignee: LIPOCINE INC.
    Inventors: Satish Kumar Nachaegari, Chandrashekar Giliyar, Chidambaram Nachiappan, Mahesh V. Patel, Srinivasan Venkateshwaran
  • Patent number: 9364563
    Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: June 14, 2016
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MOLECULAR EXPRESS, INC.
    Inventors: Gary Fujii, Francis C. Szoka, Jr., Douglas S. Watson
  • Patent number: 9365608
    Abstract: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: June 14, 2016
    Assignee: Ohr Pharmaceutical, Inc.
    Inventors: Michael McLane, Inez Ruiz-White, Henry Wolfe
  • Patent number: 9358298
    Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: June 7, 2016
    Assignee: LIPOCINE INC.
    Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
  • Patent number: 9340569
    Abstract: Certain bile acids, including novel bile acids, and derivatives thereof can be used to inhibit the germination of C. difficile spores and/or the growth of C. difficile cells. The methods and compositions of the invention are useful for preventing and treating C. difficile-associated diseases, including but not limited to C. difficile colitis.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: May 17, 2016
    Assignee: Tufts University
    Inventors: Joseph Sorg, Abraham L. Sonenshein
  • Patent number: 9321802
    Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: April 26, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Shunlin Ren, William M. Pandak
  • Patent number: 9314472
    Abstract: Treating and Preventing mastitis employing cationic steroidal antimicrobials (CSAs). Treating or preventing clinical mastitis in a mammal includes administering a cationic steroidal anti-microbial compound (CSA) formulation to the intra-mammary organ of a mammal (e.g., a dairy cow), such as by injection into the mammary organ (e.g., through the teat of the mammary organ), and/or topical application. The dairy cow can be lactating and have a somatic cell count (SCC) less than or equal to 500,000 cells/mL at the time of administering the CSA formulation. Alternatively, the dairy cow can be lactating and have a somatic cell count (SCC) greater than 500,000 cells/mL at the time of administering the CSA formulation. The dairy cow can be taken out of production during the administration of the CSA formulation for a period of time of about 3 days or less, 2 days or less, or 1 day or less.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: April 19, 2016
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Chad S. Beus, Paul B. Savage
  • Patent number: 9295677
    Abstract: The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis of portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2?,3?,7?,12?-tetrahydroxy-5?-cholanoic acid and 3?.4?,7?,12?-tetrahydroxy-5?-cholanoic acid are disclosed, uses thereof and synthesis thereof.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: March 29, 2016
    Assignee: Qing Bile Therapeutics Inc.
    Inventors: Victor Ling, Renxue Wang, Jonathan Ahab Sheps
  • Patent number: 9290779
    Abstract: A low toxicity, highly efficient transfection composition is described with an amphipathic compound containing at least one imidazole. The composition may be used in the process of transfecting nucleic acids into an animal cell.
    Type: Grant
    Filed: June 15, 2014
    Date of Patent: March 22, 2016
    Inventors: Laura Juckem, Karen Neder, James Hagstrom, Jon Wolff
  • Patent number: 9243027
    Abstract: The invention relates to compounds of Formula A: or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: January 26, 2016
    Assignee: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: Roberto Pellicciari
  • Patent number: 9168262
    Abstract: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: October 27, 2015
    Assignee: The Regents of the University of California
    Inventor: Rhonda R. Voskuhl
  • Patent number: 9156876
    Abstract: The present invention is directed to a process for conferring cytoprotection on a population of cells which comprises administering to that population of cells a compound comprising a hydroxy-substituted aromatic ring structure and a non-fused polycyclic, hydrophobic substituent attached thereto. In particular, the present invention is directed to such a process wherein the administered compound is phenolic, such as a steriod (e.g., estrogen), and has a non-fused polycyclic, hydrophobic substituent attached to the hydroxy-substituted A-ring thereof.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 13, 2015
    Assignee: Washington University
    Inventor: Douglas F. Covey
  • Patent number: 9144553
    Abstract: The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 29, 2015
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Edward Kisak, Nadir Buyuktimkin, Servet Buyuktimkin, John Newsam, Jianye Wen, Jutaro Shudo, Amit Jain